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Abstract
Objective: The aim of this study was to investigate the correlations among circulating osteoprotegerin (OPG),
the receptor activator of nuclear factor-JB ligand (RANKL), high-sensitivity C-reactive protein (hsCRP), and bone
mineral density (BMD) in healthy postmenopausal women.
Methods: In a population-based study, highly specific enzyme-linked immunosorbent assay methods were used
to evaluate the sera of 382 healthy Iranian postmenopausal women (mean age T SD, 58.7 T 7.5 y) for RANKL,
OPG, hsCRP, degradation products of C-terminal telopeptides of type I collagen, and osteocalcin. BMD was
determined for the lumbar spine (L2-L4) and the proximal femur using dual-energy x-ray absorptiometry.
Results: Circulating levels of OPG (r = 0.30, P G 0.001) and the RANKL/OPG ratio (r = j0.17, P G 0.001)
were significantly associated with age. The geometric mean of hsCRP was 1.89 mg/L (SE, 1.05) in the population
studied. There was a significant correlation between log(hsCRP) levels and body mass index (BMI; r = 0.36, P G
0.001). Multivariate linear analyses revealed that age (A = j0.295, P G 0.001), BMI (A = 0.464, P G 0.001),
RANKL (A = j0.105, P = 0.014), and OPG (A = 0.098, P = 0.029) were the independent determinants for lumbar
BMD (R2 = 0.35). Age (A = j0.250, P G 0.001), BMI (A = 0.486, P G 0.001), and RANKL (A = j0.110, P =
0.009) were independently correlated with femoral neck BMD (R2 = 0.36). Age- and BMI-adjusted analysis by
quartiles of log-transformed hsCRP did not reveal an association with BMD, serum levels of biochemical markers
of bone turnover, RANKL, or OPG.
Conclusions: The circulating levels of the RANKL/OPG osteoimmunity system have an association with BMD,
but subclinical systemic inflammation may not be involved in bone mass in healthy postmenopausal women.
Key Words: Receptor activator of nuclear factor-JB ligand Y Osteoprotegerin Y C-reactive protein Y
Inflammation Y Bone mineral density.
A
balance of the two peptides produced by osteoblasts,
osteoprotegerin (OPG) and the receptor activator of
nuclear factor-JB ligand (RANKL), is essential for
osteoclast function and bone remodeling.1 RANKL is a
cytokine belonging to the tumor necrosis factor (TNF) family
that binds to membrane-bound receptor RANK on osteoclasts
and promotes differentiation of marrow cells through various
stages to multinucleated osteoclasts that resorb bone.2 OPG
acts as a blocking receptor by binding to RANKL and
preventing it from binding to RANK.3,4
Most of the factors that induce RANKL expression by
osteoblasts also regulate OPG expression.5 Systemic factors
such as glucocorticoids, immunosuppressants, and estrogen
deficiency and continuous exposure of parathyroid hormone
increase the RANKL/OPG ratio.1 Thus, the relative concen-
tration of RANKL and OPG in bone is a major determinant
of bone health.
The RANK/RANKL/OPG system has also been shown to
modulate dendritic cells and activate T cells, as well as to
promote B-cell maturation and antibody response, which
suggests that this system plays an important role in both the
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skeletal and immune systems.6 This osteoimmunological
system configures interesting molecular links between bone
remodeling, immunity, and inflammation.7,8
Measurement of the concentration of C-reactive protein
(CRP), an acute-phase reactant, has been used as a sensitive
marker of chronic, low-grade systemic inflammation. CRP is
produced by the liver under induction by interleukin (IL) 1,
IL-6, and TNF->.7 The mechanism linking high-sensitivity
CRP (hsCRP) and bone metabolism has not been completely
clarified, but substantial evidence that certain inflammatory
cytokines, including IL-1, IL-6, and TNF->, are likely to be
involved is suggested.9 Previous studies also reported that the
serum hsCRP level was a significant predictor of osteoporotic
fracture.10,11 Therefore, chronic, low-grade inflammation
could be considered an important factor in lower bone
mineral density (BMD) in postmenopausal osteoporosis.
Investigations in humans under various conditions and
disease states have examined serum levels of OPG and/or
RANKL with conflicting results.12 However, the relationship
of the RANKL/OPG system, subclinical inflammation, and
BMD in healthy postmenopausal women has not been
adequately examined. This is of primary importance because
the interaction of osteoimmunity and chronic, low-grade in-
flammation on bone remodeling remains to be clarified. Thus,
the aim of this study was to investigate the relationships be-
tween serum concentrations of OPG, RANKL, OPG/RANKL
ratio, hsCRP, and BMDs in Iranian postmenopausal women.
METHODS
Community sampling and physical examinations
The study design has been described previously.13 How-
ever, in brief, participants in the present study were an age-
stratified random sample of postmenopausal women who
participated in the extension part of the Iranian Multicentral
Osteoporosis Study. They were randomly selected from 13
clusters in Bushehr port (the center of Bushehr Province,
which has the longest border with the Persian Gulf). All were
community dwelling and ambulatory.
The following exclusion criteria were used: (1) the known
presence of generalized bone diseases including hyperpara-
thyroidism, hypoparathyroidism, thyroid disorders, rheumatoid
arthritis, Cushing disease, and steroid-induced osteoporosis;
renal osteodystrophy; or other metabolic diseases; (2) a history
of malignant diseases and liver diseases; (3) drug addiction;
and (4) restriction to bed rest within the last 2 weeks after an
illness or complete bed rest for 3 months.
Height and weight were measured using a stadiometer.
Heavy outer garments and shoes were removed before height
and weight were measured. Waist circumference was defined
at the midway level between the costal margins and the iliac
crests. Hip circumference was measured at the level of the
greater trochanters.
BMD was determined for the lumbar spine (L2-L4) and
proximal femur (neck) using dual-energy x-ray absorptiom-
etry on an Osteocore II bone densitometer (Osteocore II
Osteodensitometer; Medilink, France). To eliminate operator
discrepancies, the same operator tested all the women during
the study. Duplicate measurements were obtained from 30
women who were agreeable to undergoing a repeat assess-
ment on the same day, and the precision errors were
calculated using the root mean square method. The coef-
ficients of variation (CVs; precision) of measurements of
the lumbar spine and femoral neck were 0.8% and 1.6%,
respectively.
Laboratory measurements
Measurement of CRP by an hsCRP assay, CRP HS
enzyme-linked immunosorbent assay (ELISA; DRG Interna-
tional, Inc., Mountainside, NJ), was conducted. The detect-
able concentration of the CRP HS ELISA assay was
estimated to be 0.1 mg/L. In addition, the functional
sensitivity was determined to be 0.1 mg/L (as determined
with interassay %CV G20%).
Serum OPG levels were measured using an ELISA
commercial kit (Biomedica Gruppe, Vienna, Austria). The
detection limit of the assay was 2.8 pg/mL. The mean intra-
assay and interassay CVs of the OPG assay were 4% to 10%
and 7% to 8%, respectively.
RANKL levels were measured using an ELISA with an
additional enhancement system (ampli-sRANKL; Biomedica
Gruppe). The detection limit of the assay was 0.4 pg/mL. The
mean intra-assay and interassay CVs of the RANKL assay
were 8% to 9% and 6% to 3%, respectively.
The Serum CrossLaps ELISA (Nordic Bioscience Diag-
nostics A/S, Herlev, Denmark) was used to quantify the
degradation products of C-terminal telopeptides of type I col-
lagen in sera. The intra-assay CVs for the low (0.242 ng/mL),
medium (0.375 ng/mL), and high (0.476 ng/mL) values were
5.4%, 5.0%, and 5.1%, respectively.
The N-MID Osteocalcin ELISA (Nordic Bioscience
Diagnostics A/S) was used for the quantitative measurement
of osteocalcin in sera. The intra-assay CVs for the low
(7.0 ng/mL), medium (21.8 ng/mL), and high (43.2 ng/mL)
values were 3.4%, 2.0%, and 2.4%, respectively.
Statistical analysis
The distribution of variables was studied using probability
plots and the Shapiro-Wilk test. We found that log trans-
formation of CrossLaps, osteocalcin, hsCRP, OPG, and
RANKL gave a better fit to a gaussian distribution. The
geometric mean for those biochemical variables was defined
as the arithmetic mean of the log-transformed data T 2 SD,
raised to the power of 10.
Pearson’s correlation analysis was used to study the
relationships among the anthropometric and biochemical
variables and the BMD measurements. The association of
log(hsCRP) quartiles (Qs) with BMD, the RANKL/OPG
system, and markers of bone turnover was also determined
using analysis of covariance.
Multiple linear models were used to explore the effects of
the RANKL/OPG system or hsCRP concentrations on BMD
after adjustment for covariates. Age and body mass index
(BMI) were considered as covariates in the linear regression
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models because these variables significantly correlated with
BMDs in univariate analyses. Multivariate linear analyses
were also performed to investigate the independent effect of
age, BMI, RANKL, OPG, and hsCRP on BMD at the lumbar
or femoral neck areas in separate models. All the independent
variables were entered at once. A P value less than 0.05 was
accepted as the value of significance.
Statistical analysis was performed with an IBM computer
using the SPSS 9.05 statistical software package (SPSS Inc.,
Chicago, IL).
RESULTS
The characteristics of the study participants are shown in
Table 1. The prevalence of consumption of oral calcium,
vitamin D supplementation, and use of hormone therapy was
5.7%, 4.2%, and 1.0%, respectively. According to the World
Health Organization criteria, 150 (39.3%) and 127 (33.2%)
women were considered osteopenic/osteoporotic at the
lumbar and femoral neck sites, respectively.14
BMD at the lumbar spine and femoral neck decreased
progressively as age increased (P G 0.001). There were
significant positive associations between BMI and BMD at
all sites (P G 0.001). However, there was no significant
correlation between waist-to-hip ratio and BMD at the
lumbar and femoral sites (P 9 0.05).
The geometric mean of CRP was 1.89 mg/L (SE, 1.05) in the
studied population. Qs for the population distribution for CRP
were as follows: Q1, 0.03-1.05 mg/L; Q2, 1.06-2.00 mg/L; Q3,
2.01-4.22 mg/L; and Q4, 4.23-26.91 mg/L. Serum levels of
log(hsCRP) had a significant correlation with BMI (r = 0.36,
P G 0.001) and waist-to-hip ratio (r = 0.16, P = 0.002).
The OPG (r = 0.30, P G 0.001) and RANKL/OPG ratio
(r = j0.17, P G 0.001) levels were significantly associated
with age. Age-adjusted serum levels of OPG showed no
association with BMD at the lumbar and femoral sites, but
age-adjusted RANKL and the RANKL/OPG ratio were
negatively associated with BMD at the lumbar (r = j0.12,
P = 0.019 and r = j0.13, P = 0.007, respectively) and fem-
oral neck (r = j0.13, P = 0.012 and r = j0.12, P = 0.020,
respectively) sites.
In multiple regression models, serum concentrations of
RANKL (negatively) and the RANKL/OPG ratio (positively)
were significantly related to BMD at the lumbar and femoral
neck sites, and OPG was found to be significantly correlated
with lumbar BMD (Table 2). The correlations of the
RANKL/OPG regulatory system with BMD remained when
log(hsCRP) was considered as a covariate to the baseline
regression models (data not shown).
Multivariate linear analyses were also performed to inves-
tigate the independent effect of age, BMI, RANKL, OPG,
and hsCRP on BMD at the lumbar or femoral neck areas.
The results revealed that age (A = j0.295, P G 0.001),
BMI (A = 0.464, P G 0.001), RANKL (A = j0.105, P =
0.014), and OPG (A = 0.098, P = 0.029) were the
independent determinants for lumbar BMD (R2 = 0.35).
Age (A = j0.250, P G 0.001), BMI (A = 0.486, P G 0.001),
and RANKL (A = j0.110, P = 0.009) were independently
correlated with femoral neck BMD (R2 = 0.36).
There was no significant age- and BMI-adjusted linear
correlation between log(hsCRP) concentrations and BMD in
either the lumbar spine or the proximal femur (Table 2).
Age- and BMI-adjusted analysis by Qs of log(hsCRP) did
not reveal an association with BMD, RANKL, OPG,
RANKL/OPG ratio levels, or circulating bone turnover
marker concentrations (data not shown).
In addition, the RANKL, OPG, and RANKL/OPG serum
levels were not related to logarithmically transformed serum
CrossLaps and osteocalcin concentrations.
DISCUSSION
We found that serum RANKL levels were negatively
related to BMD at the femoral neck and lumbar spine, and
circulating OPG concentrations were positively correlated to
TABLE 1. Basic characteristics of bone-related variables in an
Iranian postmenopausal population (382 participants)
Mean SD
Age, y 58.71 7.50
Body mass index, kg/m2 28.34 4.73
Waist-to-hip ratio 0.92 0.06
RANKL, pg/mLa 1.59 3.00
OPG, pg/mLa 72.44 1.55
RANKL/OPG ratio 0.04 0.05
CrossLaps, ng/mLa 591.56 1.69
Osteocalcin, ng/mLa 11.45 1.85
hsCRP, mg/La 1.89 2.84
Femoral neck BMD, g/cm2 0.844 0.184
Wards triangle BMD, g/cm2 0.608 0.252
Trochanter BMD, g/cm2 0.632 0.148
Lumbar BMD, g/cm2 0.946 0.186
Data are means and SDs. RANKL, receptor activator of nuclear factor-JB
ligand; OPG, osteoprotegerin; hsCRP, high-sensitivity C-reactive protein;
BMD, bone mineral density.
aGeometric mean (SD).
TABLE 2. Age- and BMI-adjusted standardized A coefficients for the multiple linear regressions of circulating levels of RANKL/OPG
regulatory system and hsCRP with bone mineral densities in an Iranian postmenopausal population (382 women)
Lumbar spine Trochanter Femoral neck Wards triangle
A P A P A P A P
RANKL j0.102 0.017 j0.060 0.162 j0.110 0.009 j0.018 0.663
OPG 0.101 0.022 j0.004 0.924 0.027 0.532 0.054 0.204
RANKL/OPG ratio j0.131 0.003 j0.050 0.210 j0.114 0.008 j0.034 0.421
hsCRP 0.004 0.932 0.031 0.486 0.012 0.780 j0.016 0.710
All the variables were log transformed for analyses. BMI, body mass index; RANKL, receptor activator of nuclear factor-JB ligand; OPG, osteoprotegerin;
hsCRP, high-sensitivity C-reactive protein.
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BMD at the lumbar spine, independent of age and BMI, in
healthy, Iranian postmenopausal women.
The OPG/RANKL/RANK cytokine system is essential for
osteoclast biology, and accumulating evidence suggests the
role of this system in many clinically relevant metabolic bone
diseases in humans.1
In postmenopausal osteoporosis, polymorphisms in the
TNF superfamily member 11 gene (that codes for RANKL)
promoter were associated with BMD.15 The OPG and
RANKL gene polymorphism was identified as a genetic
factor associated with BMD of the lumbar spine in Korean
women.16 Recently, denosumab, as a fully human mono-
clonal antibody that inhibits bone resorption by neutralizing
RANKL, showed significantly larger gains in BMD and
greater reduction in bone turnover markers compared with
alendronate.17
Because of these findings, the circulating RANKL and
OPG are likely to be involved in the pathogenesis of
postmenopausal osteoporosis. However, recent attempts to
measure the serum levels of RANKL and OPG as well as
BMD measurements in postmenopausal women yielded
mixed results. Serum RANKL levels were reported not to
be associated with BMD18<20 and were negatively related
with lumbar BMD.21 However, a low level of soluble
RANKL was an independent predictor of nontraumatic
fracture.22 Serum OPG levels have also been found to be
positively, negatively, or not related to BMD in postmeno-
pausal women (reviewed in References 12 and 23). A higher
OPG concentration was associated with greater femoral neck
bone density in postmenopausal women in the Framingham
Offspring Study.24 In the Rancho Bernardo Study,25 serum
OPG levels were significantly positively associated with
BMD at the femoral neck, total hip, and lumbar spine in
women using estrogen but not in nonusers of estrogen.
Despite clear changes in RANKL expression in marrow
cells, Eghbali-Fatourechi et al26 did not detect differences in
circulating RANKL levels in their study, highlighting the
importance of assessing the levels of these factors directly in
the bone microenvironment. The levels of RANKL in the
bone microenvironment may be more relevant, but only a
few studies have attempted to investigate this.12
These conflicting findings raise the concern that measure-
ment of circulating levels of these cytokines may not be
clinically relevant in postmenopausal osteoporosis. There-
fore, the relationship between the RANKL/OPG regulatory
system and BMD in our study should be interpreted with
caution. However, our findings suggest that these regulatory
circulating cytokines may be considered potential markers for
BMD and postmenopausal osteoporosis.
The RANK/RANKL/OPG regulatory system mediates the
effects of systemic factors such as parathyroid hormone,
1,25-dihydroxyvitamin D, and interleukin 1 on bone resorp-
tion.2 Conceptually, it is therefore reasonable to think about
the effect of systemic chronic inflammation on bone
metabolism in terms of the RANK/RANKL/OPG system. In
inflammatory or autoimmune disease states, as part of the
autoimmune process, activated T cells produce RANKL and
proinflammatory cytokines, all of which can induce RANKL
expression in osteoblasts.7 RANKL gene expression has been
found in cells in the synovial tissues of inflamed joints,
indicating the importance of RANKL in the pathogenesis of
joint damage.2 Recently, a significant correlation was
reported between serum RANKL and CRP in rheumatoid
arthritis.27 However, no publication on the relationship
between serum RANKL and BMD in healthy individuals
with subclinical inflammation could be found. In the present
study, for the first time, we showed that beyond the RANKL/
OPG regulatory system, chronic low-grade inflammation did
not account for any variance in BMD at all sites.
There is little information about the serum levels of
RANKL/OPG and circulating hsCRP in postmenopausal
women. The only published study reported that serum OPG
values were elevated regardless of high bone turnover, in a
close relationship with the serum CRP measurement in long-
lived participants (age range, 85-110 y).28 There was no
significant correlation between RANKL or OPG and hsCRP
in the present study. Therefore, chronic low-grade inflamma-
tion would not seem to be an important factor influencing
these cytokine serum concentrations.
TNF has been indirectly implicated in postmenopausal and
inflammation-associated bone loss. Interestingly, TNF (like
RANKL) can induce the sequential expression of nuclear
factor JB, c-Fos, and nuclear factor of activated T-cells c1,
thereby directly controlling the differentiation of osteoclast
precursors into osteoclasts. IL-1 does not activate c-Fos, but
in osteoclast precursors in which c-Fos has been activated,
for example, by RANKL or TNF, IL-1 can induce osteoclas-
togenesis directly. This leads to more osteoclast formation
using the same NFATc1-activated mechanism as RANKL
(reviewed in References 5 and 29). Thus, TNF by inducing
c-Fos expression in osteoclast precursors at the sites of
inflammation could facilitate a direct induction of osteoclas-
togenesis by IL-1.30 This TNF signaling could describe the
pathological mechanism of inflammatory conditions, such as
rheumatoid arthritis and inflammatory bone diseases, on bone
resorption. However, we think that this mechanism does not
seem to play a major role in the chronic, low-grade
inflammatory state as manifested by high levels of hsCRP
in healthy participants because we did not find an association
between hsCRP levels and BMD in multiple regression
analysis models in healthy postmenopausal women.
Three cross-sectional studies have analyzed the relation-
ship between CRP and BMDs.31<33 Two of these previous
studies31,32 showed that CRP was not associated with bone
mass in healthy postmenopausal women after multivariate
analysis. However, in a cross-sectional study, Koh et al33
showed that higher serum hsCRP levels were associated with
lower BMD in a large population of Korean women. As a
limitation of this study, the study population was composed
of women who visited a health promotion center and may
not have been representative of the general population.34
However, in the present population-based study, we did not
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find a significant association between hsCRP and BMD at the
lumbar and femoral sites in postmenopausal women residing
in a community. Our results are consistent with the other
previous studies.31,32 Pasco et al,11 who reported circulating
hsCRP as an independent predictor of fracture risk in older
women, also showed no significant correlation between
hsCRP and BMD in their study. These conflicting results
suggest that further studies are needed to examine hsCRP as a
potential marker of postmenopausal osteoporosis.
The relationship between bone turnover rate and hsCRP
has been investigated by three previous studies.9,11,34 Kim
et al34 found an association between urinary N-terminal
telopeptide of type I collagen and serum hsCRP levels in 150
postmenopausal women. Ding et al,9 in their longitudinal
study, reported that a change in the urinary pyridinoline-to-
creatinine ratio was positively associated with hsCRP.
However, Pasco et al,11 in their large population-based study,
found no significant correlations between hsCRP and serum
C-telopeptide as a marker of bone resorption. We also did not
find an association between hsCRP and serum CrossLaps and
osteocalcin as bone turnover markers.
When the results of the RANKL/OPG regulatory system in
serum are analyzed, several limitations should be considered.
First, we measured these cytokines in serum, and it is unclear
to what extent this correlates to local cytokine production or
action within the bone microenvironment. Second, RANKL
and OPG are not bone-specific and are produced by various
nonskeletal tissues.5 Third, we acknowledge that the cross-
sectional design of our study could not determine if there is a
causal relationship between the RANKL/OPG regulatory
system and BMD measurements. In addition, we did not
measure inflammatory cytokines, including IL-1, IL-6, and
TNF->, that may better configure low-grade, subclinical
inflammation in healthy individuals.
Despite these potential limitations, we found a negative
relationship between RANKL, the RANKL/OPG ratio, and
BMD at the lumbar and femoral neck and a positive relation-
ship between OPG and lumbar BMD. The cross-sectional
design prohibits conclusions regarding a causal relation
between the circulating RANKL/OPG system and bone health
indices examined in this investigation. Therefore, the clinical
significance of circulating levels of these cytokines in osteo-
porosis needs prospective studies in different populations.
CONCLUSIONS
We found a negative relationship between circulating
RANKL, the RANKL/OPG ratio, and BMD at the lumbar
and femoral neck and a positive relationship between OPG
and BMD at the lumbar spine. These findings suggest that the
components of the RANKL/OPG osteoimmunological sys-
tem may provide clinical and biological clues for treatment
and prevention of postmenopausal osteoporosis in the future.
In this population-based study, serum hsCRP concentrations
were not associated with BMD at either site, circulating
levels of RANKL/OPG system, and markers of bone turn-
over. Therefore, subclinical systemic inflammation may not
be involved in the pathogenesis of osteoporosis. In con-
clusion, it seems that the osteoimmunity system is more
important than subclinical inflammation in bone mass of
healthy postmenopausal women.
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